Scribe’s early-stage IPO standout defies biotech’s derisking trend
Scribe’s early-stage IPO standout defies biotech’s derisking trend
InVivoScribe
Biopharmaceutical company
Biopharmaceutical company
Scribe’s early-stage IPO standout defies biotech’s derisking trend